Targeting ribosome biogenesis sensitizes PARPi-resistant triple-negative breast cancer
Poly (ADP-ribose) polymerase inhibitors (PARPi) are the only targeted treatment available for early triple-negative breast cancer (TNBC), an aggressive subtype with limited treatment options. While PARPi are effective in patients with BRCA mutations, resistance to these inhibitors can arise. We previously developed BRCA-mutant cell lines, HCC1395, with acquired resistance to talazoparib and…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
